{"id":"NCT02100514","sponsor":"Pfizer","briefTitle":"Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events","officialTitle":"A 52 Week Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-10-28","primaryCompletion":"2016-07-15","completion":"2017-07-10","firstPosted":"2014-04-01","resultsPosted":"2017-07-21","lastUpdate":"2018-07-31"},"enrollment":746,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Hyperlipidemia"],"interventions":[{"type":"DRUG","name":"Bococizumab (PF-04950615; RN316)","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Bococizumab (PF-04950615; RN316)","type":"EXPERIMENTAL"},{"label":"placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study is a multicenter, double-blind, randomized study to access the efficacy, safety and tolerability of Bococizumab (PF-04950615; RN316) in subjects with hyperlipidemia receiving background statin therapy.","primaryOutcome":{"measure":"Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12","timeFrame":"Baseline, Week 12","effectByArm":[{"arm":"Treatment Period: Placebo","deltaMin":-0.8,"sd":17.61},{"arm":"Treatment Period: Bococizumab 150 mg","deltaMin":-50.8,"sd":29.81}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":223,"countries":["United States","Canada","Czechia","Finland","Netherlands","Norway","Poland","Puerto Rico","Singapore","South Korea","Sweden","United Kingdom"]},"refs":{"pmids":["37994400","37658997","35277540","29685591","28304227"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1481045&StudyName=Randomized%20Clinical%20Trial%20of%20RN316%20%28PF-04950615%29%20inSubjects%20With%20Primary%20Hyperlipidemia%20or%20Mixed%20Dyslipidemia%20At%20Risk%20Of%20Cardiovascular%20"]},"adverseEventsSummary":{"seriousAny":{"events":32,"n":247},"commonTop":["Injection site reaction","Upper respiratory tract infection","Nasopharyngitis"]}}